Zealand Pharma partners with Generate Biomedicines on AI‑driven protein therapeutics for obesity and metabolic disease
Zealand Pharma and Generate Biomedicines announced a collaboration to create AI‑designed multispecific protein drugs targeting obesity and related metabolic conditions. Generate will be paid $30 million at signing and can earn up to $35 million by reaching early pre‑clinical milestones for the first two programs. Additional milestone payments could total nearly $1.2 billion, and Generate will also receive royalties on future sales. Zealand will lead clinical development, regulatory work and worldwide commercialization.
Why it matters
The agreement gives Zealand access to Generate’s generative‑AI platform, potentially accelerating its pipeline of protein therapeutics and expanding its product toolbox beyond small‑molecule and peptide assets. Investors should note the $30 million upfront cash outlay and the large contingent milestone pool, which could affect Zealand’s cash flow and earnings if milestones are achieved.
Key facts
- 1Generate will receive $30 million at signing and may earn up to $35 million by meeting early pre‑clinical milestones for two initial programs. investing.com
- 2Total potential milestone payments to Generate are nearly $1.2 billion, covering development, regulatory and commercial milestones, plus tiered royalties on worldwide net sales. investing.com
- 3Zealand will be responsible for clinical development, regulatory submissions and worldwide commercialization of the resulting therapeutics. investing.com
- 4The collaboration includes an option to add a third program beyond the two initial ones. investing.com
- 5Utpal Singh, Chief Scientific Officer of Zealand Pharma, said the partnership expands the company’s toolbox to include protein therapeutics. investing.com
- 6Mike Nally, CEO of Generate Biomedicines, highlighted the combination of Zealand’s peptide expertise with Generate’s AI platform to address unmet cardiometabolic needs. investing.com
Summary written by AlphAI AI Desk from 6 of 6 sources. Not investment advice. Figures are as stated by the linked sources.